Lineen James R, Kuliszewski Michael, Dacouris Niki, Liao Christine, Rudenko Dmitriy, Deva Djeven P, Goldstein Marc, Leong-Poi Howard, Wald Ron, Yan Andrew T, Yuen Darren A
Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON Canada.
Department of Medical Imaging, St. Michael's Hospital, Toronto, ON Canada.
Can J Kidney Health Dis. 2015 Jul 30;2:25. doi: 10.1186/s40697-015-0060-y. eCollection 2015.
Left ventricular hypertrophy (LVH) is commonly found in chronic dialysis (CD) recipients, and is associated with impaired microvascular cardiac perfusion and heart failure. In response to LVH and cardiac ischemia, early outgrowth pro-angiogenic cellS(EPCs) mobilize from the bone marrow to facilitate angiogenesis and endothelial repair. In the general population, EPC number and function correlate inversely with cardiovascular risk. In end-stage renal disease (ESRD), EPC number and function are generally reduced.
To test whether left ventricular abnormalities retain their potent ability to promote EPC reparative responses in the setting of ESRD.
Cross-sectional study.
St. Michael's Hospital, Toronto, Ontario, Canada.
47 prevalent chronic dialysis recipients.
(1) circulating CD34(+) and CD133(+) EPC number, (2) cultured EPC migratory ability, in vitro differentiation potential, and apoptosis rate, and (3) cardiac magnetic resonance-measured LV mass, volume and ejection fraction.
Bivariate correlation analysis was performed with Spearman's rho test.
Of the 47 patients (mean age: 54 ± 13 years), the mean delivered urea reduction was 74 ± 10 %. Mean LV mass was 123 ± 38 g. Circulating CD34(+) and CD133(+) EPCs represented 0.14 % (IQR: 0.05 - 0.29 %) and 0.05 % (IQR: 0.01 - 0.10 %) of peripheral blood mononuclear cells. There were no significant correlations between any EPC parameter and measures of LV mass or ejection fraction.
Lack of a non-ESRD control population, and the inability to measure all parameters of EPC function due to limitations in blood sampling. Our inability to measure cardiac VEGF expression prevented an assessment of changes in cardiac EPC mobilization signals.
These data suggest that in ESRD, the reparative EPC response to cardiac hypertrophy may be blunted. Further investigation of the effects of uremia on EPC physiology and its relationship to cardiac injury are required.
左心室肥厚(LVH)常见于慢性透析(CD)患者中,且与微血管心脏灌注受损及心力衰竭相关。为应对LVH和心脏缺血,早期生长的促血管生成细胞(EPCs)从骨髓动员出来以促进血管生成和内皮修复。在普通人群中,EPC数量和功能与心血管风险呈负相关。在终末期肾病(ESRD)中,EPC数量和功能通常会降低。
测试在ESRD情况下左心室异常是否仍保留其促进EPC修复反应的强大能力。
横断面研究。
加拿大多伦多安大略省圣迈克尔医院。
47名慢性透析患者。
(1)循环中CD34(+)和CD133(+) EPC数量,(2)培养的EPC迁移能力、体外分化潜能和凋亡率,以及(3)心脏磁共振测量的左心室质量、容积和射血分数。
采用Spearman等级相关检验进行双变量相关分析。
47例患者(平均年龄:54±13岁),平均尿素清除率为74±10%。平均左心室质量为123±38g。循环中的CD34(+)和CD133(+) EPC分别占外周血单个核细胞的0.14%(四分位间距:0.05 - 0.29%)和0.05%(四分位间距:0.01 - 0.10%)。EPC的任何参数与左心室质量或射血分数的测量值之间均无显著相关性。
缺乏非ESRD对照人群,且由于采血限制无法测量EPC功能的所有参数。我们无法测量心脏VEGF表达,从而无法评估心脏EPC动员信号的变化。
这些数据表明,在ESRD中,EPC对心脏肥大的修复反应可能减弱。需要进一步研究尿毒症对EPC生理学的影响及其与心脏损伤的关系。